Development PipelineTucatinib

a highly selective small molecule tyrosine kinase inhibitor being investigated in multiple HER2-overexpressed/amplified and HER2-mutated cancers

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Clinical Trials

CompassHER2 RD: HER2+ breast cancer (tucatinib or placebo + T-DM1)

ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

HER2CLIMB-02: HER2+ metastatic breast cancer (tucatinib or placebo +T-DM1)

ClinicalTrials.Seagen.com ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

HER2CLIMB-05: HER2+ metastatic breast cancer (tucatinib or placebo + trastuzumab + pertuzumab)

ClinicalTrials.Seagen.com ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

MOUNTAINEER-03: HER2+ metastatic colorectal cancer (tucatinib + trastuzumab + mFOLFOX6 vs mFOLFOX6 ± cetuximab or bevacizumab)

ClinicalTrials.Seagen.com ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

HER2CLIMB-04: HER2+ metastatic breast cancer (tucatinib + T-DXd)

ClinicalTrials.Seagen.com ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

SGNTUC-019: Locally advanced or metastatic solid tumors driven by HER2 alterations (tucatinib + trastuzumab)

ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

SGNTUC-024: HER2+ metastatic gastrointestinal cancers (tucatinib + trastuzumab ± pembrolizumab ± FOLFOX or CAPOX)

ClinicalTrials.Seagen.com ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

Program Resources

High-level synopsis of tucatinib and ongoing clinical trials

View/Download

Detailed information about tucatinib clinical trials

View in Interactive Pipeline